Integer Holdings Corporation has been granted early termination of the waiting period under the Hart-Scott-Rodino Act for its proposed acquisition by KKR, clearing the principal United States antitrust condition on the transaction. The grant was made on 30 September 2026.
The deal values Integer at 127.00 dollars per share in cash, an enterprise value of roughly 5.7 billion dollars. A stockholder vote on the transaction is scheduled for the twenty first of October.
A grant, not an expiry
The distinction matters more than it first appears. A Hart-Scott-Rodino waiting period ordinarily runs its full thirty days and simply lapses, and most deal announcements describe the clock running out. Early termination is an affirmative act: the Federal Trade Commission and the Department of Justice have to decide the transaction raises no competitive question worth the remaining days and then say so publicly.
That affirmative grant has become scarce. The agencies suspended early termination entirely in 2021 and have restored it only selectively since, so receiving one is now a meaningful signal about how the reviewing agency reads a transaction rather than a procedural footnote. For a deal in medical device contract manufacturing, where the buyer is a financial sponsor rather than a competitor, the absence of horizontal overlap is the straightforward explanation.
What remains between here and closing
Antitrust clearance removes the condition most capable of delaying or reshaping a transaction, but it does not close it. The stockholder vote later in October is the next gate, and foreign merger control and regulatory consents in other jurisdictions typically run on their own timetables regardless of what the United States agencies decide.
For a sponsor-backed take-private the more informative question is usually financing rather than competition, and an early termination tells investors nothing about that. What it does do is compress the period of uncertainty: the spread between the market price and the 127.00 dollar offer is a direct measure of how probable the market thinks completion is, and removing antitrust risk from that calculation ordinarily narrows it.
Integer supplies medical devices and components to the cardiac, neuromodulation, orthopaedic and vascular markets, largely as an outsourced manufacturer to the large device companies rather than under its own brand. That position, selling into every major original equipment manufacturer rather than competing with them, is also what makes the competitive analysis simple.
